Video: Progress in the management of EGFR-mutant NSCLC in 2020: Where are we now?*July 2020*Dr. Roy Herbst addresses this question in a video. Watch it here.DonateSupport EGFRLatest NewsletterGet Social: Twitter Tweets by @egfrresistersCategoriesAdvocacy (5)Coping With Cancer (17)Events (1)Funding (1)Research (112)Stories (4)Treatments (102)Uncategorized (1) laurabbook@gmail.com2020-09-18T16:22:19-07:00Share This Post, Choose Your Platform!FacebookTwitterLinkedInTumblrPinterest Related Posts Osimertinib Penetrates Blood-Brain Barrier and Decreases Metastasis in EGFR+ NSCLC Osimertinib Penetrates Blood-Brain Barrier and Decreases Metastasis in EGFR+ NSCLC March 22nd, 2021 EGFR TKI Combination Therapies: C797S, MEK, AURORA Kinase EGFR TKI Combination Therapies: C797S, MEK, AURORA Kinase March 22nd, 2021 New Designations and Efficacy Demonstrations Push the EGFR+ NSCLC Paradigm Forward New Designations and Efficacy Demonstrations Push the EGFR+ NSCLC Paradigm Forward March 22nd, 2021 TKIs Set the Stage for Treatment in HER2-Mutant Lung Cancer, But May Be Eclipsed by ADCs TKIs Set the Stage for Treatment in HER2-Mutant Lung Cancer, But May Be Eclipsed by ADCs March 22nd, 2021